On June 22, Gladius Pharmaceuticals Inc., a new Montréal-based biotechnology firm, announced the closing of the equity financing via a cross-border vehicle of US technology developed by Sopharmia Inc. This investment will support Gladius’ development of novel drugs destined to treat major multi-drug-resistant bacterial infections.
Sharon G. Druker represented Sopharmia and Gladius on the deal, which also involved SR One (GlaxoSmithKline’s venture capital fund) and Lumira (Merck Lumira’s venture capital fund), as well as the Fonds de solidarité FTQ.
